Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.11.2022 | Case report

Trilaciclib

Various toxicities: 7 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Weiss J, et al. Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies. Clinical Lung Cancer 22: 449-460, No. 5, Sep 2021. Available from: URL: http://www.journals.elsevier.com/clinical-lung-cancer/ Weiss J, et al. Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies. Clinical Lung Cancer 22: 449-460, No. 5, Sep 2021. Available from: URL: http://​www.​journals.​elsevier.​com/​clinical-lung-cancer/​
Metadaten
Titel
Trilaciclib
Various toxicities: 7 case reports
Publikationsdatum
01.11.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-28788-2

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Multiple drugs

Case report

Entecavir

Case report

AZD-1222